VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
Arthur J. Gallagher & Co. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Arthur J. Gallagher & Co.
AJG · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Arthur J. Gallagher & Co.'s moat claims, evidence, and risks.
View AJG analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 69 / 100 for Arthur J. Gallagher & Co.).
- Segment focus: Arthur J. Gallagher & Co. has 2 segments (86% in Brokerage); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Arthur J. Gallagher & Co. has 4 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Arthur J. Gallagher & Co.
Brokerage
Insurance and reinsurance brokerage and consulting
Global
Commercial, industrial, public sector, nonprofit and other organizations; underwriting enterprises for reinsurance placements
Intermediary / broker / advisor
86%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Arthur J. Gallagher & Co. strengths
Gilead Sciences, Inc. strengths
Segment mix
Arthur J. Gallagher & Co. segments
Full profile >Brokerage
Oligopoly
Risk Management
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.